Supernus Pharmaceuticals (SUPN) Receivables (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Receivables data on file, last reported at $184.1 million in Q1 2026.

• Receivables for Q1 2026 came in at $184.1 million, up 26.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $184.1 million (up 26.4% YoY), and the FY2025 annual result was $189.6 million, up 29.8% from the prior year.
• Receivables retreated to $184.1 million in Q1 2026 per SUPN's latest filing, from $189.6 million in the prior quarter.
• Over five years, Receivables peaked at $189.6 million in Q4 2025 and troughed at $136.6 million in Q2 2023.
• A 5-year average of $154.9 million and a median of $146.2 million in 2025 frame the typical range for Receivables.
• The sharpest annual moves came in 2023 and 2025: Receivables declined 13.61% in 2023, then grew 29.8% in 2025.
• A 5-year view of Receivables shows it stood at $165.5 million in 2022, then dropped by 12.9% to $144.2 million in 2023, then rose by 1.33% to $146.1 million in 2024, then grew by 29.8% to $189.6 million in 2025, then dropped by 2.91% to $184.1 million in 2026.
• Business Quant data shows SUPN's Receivables at $184.1 million in Q1 2026, $189.6 million in Q4 2025, and $177.6 million in Q3 2025.